| Excerpt | Relevance | Reference |
|---|
| "In the patient group with visual hallucinations, mean salsolinol level was significantly increased to almost the 3-fold of those found in patients without hallucinations." | 5.29 | Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's disease. ( Jaskowski, P; Kömpf, D; Moser, A; Siebecker, F; Vieregge, P, 1996) |
| "In the patient group with visual hallucinations, mean salsolinol level was significantly increased to almost the 3-fold of those found in patients without hallucinations." | 1.29 | Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's disease. ( Jaskowski, P; Kömpf, D; Moser, A; Siebecker, F; Vieregge, P, 1996) |